Barry S. Coller, M.D.
Physician-in-Chief and Vice President for Medical Affairs, Rockefeller University, New York, NY
Barry S. Coller, M.D. is the David Rockefeller Professor of Medicine; Head, Allen and Frances Adler Laboratory of Blood and Vascular Biology; Physician-in-Chief of The Rockefeller University Hospital; and Vice President for Medical Affairs at The Rockefeller University. He is also founding Director of the Rockefeller University Center for Clinical and Translational Science and Principal Investigator of the University’s Clinical and Translational Science Award (CTSA) from the National Center for Advancing Translational Sciences. From 1993 to 2001, Dr. Coller was the Murray M. Rosenberg Professor of Medicine and Chairman of the Samuel Bronfman Department of Medicine at Mount Sinai School of Medicine in New York City. Before that he was Professor of Medicine and Chief of the Division of Hematology at Stony Brook University.
Dr. Coller’s research interests focus on platelet physiology. He developed a monoclonal antibody that inhibits platelet function and a derivative of that antibody (abciximab; ReoProÔ; Centocor). It was approved in 1994 to prevent ischemic complications of coronary interventions such as angioplasty and stent insertion. More than 5.0 million patients have been treated with abciximab. He also helped develop the VerifyNow assays (Accumetrics) to monitor antiplatelet therapy with aspirin, clopidogrel (Plavix™), and other antiplatelet drugs. Dr. Coller is the recipient or a co-recipient of twenty-two U.S. patents.
Dr. Coller has served as President of the American Society of Hematology and as founding President of the Society for Clinical and Translational Science. Dr. Coller is a member of Phi Beta Kappa, Alpha Omega Alpha, the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Medicine, and the National Academy of Sciences. He serves on the NASEM Forum on Drug Discovery, Development, and Translation, as well as the Board on Health Sciences Policy.